Compare Adaptive Biotechnologies Corp (ADPT) vs Visa Inc (V) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Visa Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Visa Inc trades at $349.11 (market cap $669.79B). The key difference: Visa Inc is far larger — about 201.1× Adaptive Biotechnologies Corp's market cap, and Visa Inc pays a 0.76% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | V | |
|---|---|---|
Market Cap | $3.33B | $669.79B |
Sector | Health | Financials |
52-Week High | $22.37 | $362.13 |
52-Week Low | $10.24 | $295.52 |
Enterprise Value | $3.19B | $680.39B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Visa (V) trades at $348.7, down 2.39% on the day, but maintains strong fundamentals with a 51.68% net income margin and consistent earnings beats. The stock is in a bullish technical trend with support at $349 and resistance at $355. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, positioning it for future growth amid a dominant market position.
The outlook remains positive with an 85% analyst buy rating and a $392.50 consensus price target, implying 12.6% upside. Key risks include competitive fintech threats and regulatory pressures, but Visa's robust cash flow and innovation in payments sustain long-term investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
